Management of Inferotemporal Visual Field Defect in Early Primary Open‑Angle Glaucoma

Clinical Significance

An inferotemporal visual‑field defect reflects structural damage to the superotemporal optic‑nerve rim and retinal‑nerve‑fiber layer, indicating early glaucomatous injury that warrants prompt treatment. 1
In the typical ISNT progression pattern, the temporal rim is the last region to thin; therefore involvement of the inferotemporal quadrant signals a concerning stage of disease severity. 2

Perform gonioscopy to verify open angles and exclude secondary causes such as pigment dispersion, pseudoexfoliation, uveitis, trauma, or corticosteroid exposure. 1
Measure central corneal thickness, because a thin cornea is a risk factor for POAG development and influences the accuracy of intra‑ocular pressure (IOP) readings. 3
Conduct a stereoscopic optic‑nerve examination looking for vertical cup elongation, focal rim thinning (especially superior/inferior), disc hemorrhages, RNFL defects, and beta‑zone parapapillary atrophy. 4
Obtain OCT imaging of the optic‑nerve head, RNFL, and macula to create a quantitative baseline for future progression analysis. 3
Perform standard automated perimetry (SAP) with 24‑2 or 30‑2 testing to confirm that the inferotemporal defect is reproducible and not an artifact. 3
Add 10‑2 visual‑field testing to evaluate the central 10° where early damage may be missed on 24‑2/30‑2 grids. 3

Set an initial target IOP at least 25 % lower than the pretreatment baseline; in a young adult with documented visual‑field loss this corresponds to moderate disease severity. 1
Consider a more aggressive target (≥30 % reduction) for younger patients with documented structural and functional damage to maximize long‑term visual preservation. 1

Clinical trial evidence demonstrates that lowering IOP reduces the risk of progression in primary open‑angle glaucoma. 5
Even when office IOP measurements are within the normal range (≈40 % of POAG patients), IOP reduction still confers benefit and should not be withheld if structural/functional damage is present. 4

Repeat visual‑field testing using the same strategy to verify the stability or progression of the inferotemporal defect. 3
Conduct serial optic‑nerve examinations and OCT imaging to detect progressive rim thinning, RNFL loss, or new disc hemorrhages, which are predictive of future field deterioration. 2
If any progression is identified in visual fields, optic‑nerve structure, or RNFL/macular imaging, lower the target IOP accordingly. 5

Do not postpone treatment while “observing” a patient; documented visual‑field loss together with corresponding optic‑nerve damage defines glaucoma that requires immediate intervention. 4
Recognize disc hemorrhages on follow‑up examinations as markers of asymmetric, focal progression that demand closer surveillance. 2

Early diagnosis and adequate IOP control generally prevent visual disability in primary open‑angle glaucoma. 5
Glaucoma is a chronic, progressive disease that necessitates lifelong monitoring to preserve visual function over the patient’s remaining decades. 4
The condition is usually bilateral, albeit often asymmetric; therefore the fellow eye should be monitored with equal vigilance. 1

Primary open-angle glaucoma (POAG) is characterized by progressive optic nerve damage and retinal ganglion cell loss with open anterior chamber angles, resulting in characteristic visual field defects 6, 7
The primary mechanism involves elevated intraocular pressure (IOP) causing mechanical stress on the optic nerve head and retinal nerve fiber layer (RNFL), though nearly 40% of POAG patients may not have elevated IOP during office measurements 7
Risk factors include older age, African race or Latino/Hispanic ethnicity, elevated IOP, family history of glaucoma, lower ocular perfusion pressure, type 2 diabetes mellitus, myopia, and thin central cornea 6, 8, 9
Acute angle-closure glaucoma occurs when the peripheral iris blocks the trabecular meshwork, preventing aqueous humor outflow and causing a sudden, dangerous rise in IOP 10
Risk factors for acute angle-closure glaucoma include Asian descent, hyperopia, older age, female gender, short axial length, thick and anteriorly positioned crystalline lens, shallow anterior chamber, steep corneal curvature, and family history 10

The primary goal of POAG treatment is to lower IOP to a target level that prevents further optic nerve damage and visual field loss 11, 12
Initial target IOP should be at least 25% lower than pretreatment levels, with more aggressive targets for severe damage or rapid progression 11, 12
Acute angle-closure glaucoma is a medical emergency requiring immediate intervention to prevent permanent vision loss 10
Initial medical therapy to lower IOP includes topical beta-blockers, alpha2-adrenergic agonists, carbonic anhydrase inhibitors, parasympathomimetics, and oral or intravenous hyperosmotic agents 10
Definitive treatment once IOP is controlled includes laser peripheral iridotomy (LPI), surgical iridectomy, prophylactic laser iridotomy in the fellow eye, and lens extraction 10

Regular assessment of optic nerve structure and function through clinical examination, imaging, and visual field testing 6, 7
Severity of glaucoma can be classified as mild, moderate, or severe based on optic disc/RNFL abnormalities and visual field defects 7, 8
For angle-closure patients after treatment, follow-up should include confirmation of iridotomy patency, IOP measurement, dark-room gonioscopy, and fundus examination 10

Delayed diagnosis of angle-closure glaucoma can lead to permanent vision loss, with 18% of eyes becoming blind and 48% developing glaucomatous optic neuropathy within 4-10 years following untreated acute angle closure 10
Patients with asthma require careful consideration when selecting glaucoma medications, as some may exacerbate respiratory symptoms 13